Samsung Biologics announced the signing of an agreement with Ichnos to manufacture the drug substance for ISB 830, a monoclonal antibody (mAb) against receptor OX40, which is currently in development as a potential treatment for moderate-to-severe atopic dermatitis.
Additionally, the product has a mechanism of action that enables the treatment of ‘a range of autoimmune diseases’, including atopic dermatitis, the companies stated.
The agreement comes as Ichnos has completed enrollment in a Phase IIb clinical study for ISB 830, with results expected during the first half of 2020, and prepares to advance the candidate into Phase III clinical trials.
A spin-out company of Glenmark, Ichnos was launched earlier this month with a portfolio of five clinical stage assets across the oncology, autoimmune disease, and pain therapeutics areas.
Samsung had signed an agreement to provide process development and manufacturing services for ISB 830 with Glenmark in 2017.
According to the companies, the prevalence of atopic dermatitis in seven major markets (US, France, Germany, Italy, Spain, the UK, and Japan) currently exceeds 80 million patients, with the market expected to grow to $18.3bn (€16.53bn) by 2027.
